Telix Free Cash Flow Yield vs Capex To Depreciation Analysis

TLX Stock

14.70 0.07 0.47%

Telix Pharmaceuticals financial indicator trend analysis is much more than just breaking down Telix Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Telix Pharmaceuticals is a good investment. Please check the relationship between Telix Pharmaceuticals Free Cash Flow Yield and its Capex To Depreciation accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telix Pharmaceuticals Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Free Cash Flow Yield vs Capex To Depreciation

Free Cash Flow Yield vs Capex To Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Telix Pharmaceuticals Free Cash Flow Yield account and Capex To Depreciation. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Telix Pharmaceuticals' Free Cash Flow Yield and Capex To Depreciation is -0.15. Overlapping area represents the amount of variation of Free Cash Flow Yield that can explain the historical movement of Capex To Depreciation in the same time period over historical financial statements of Telix Pharmaceuticals Limited, assuming nothing else is changed. The correlation between historical values of Telix Pharmaceuticals' Free Cash Flow Yield and Capex To Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Yield of Telix Pharmaceuticals Limited are associated (or correlated) with its Capex To Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Depreciation has no effect on the direction of Free Cash Flow Yield i.e., Telix Pharmaceuticals' Free Cash Flow Yield and Capex To Depreciation go up and down completely randomly.

Correlation Coefficient

-0.15

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Capex To Depreciation

The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.

Most indicators from Telix Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Telix Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telix Pharmaceuticals Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Selling General Administrative is likely to drop to about 57.5 M in 2024. Sales General And Administrative To Revenue is likely to drop to 0.15 in 2024

	2021	2022	2023	2024 (projected)
Interest Expense	5.2M	6.4M	13.1M	7.1M
Depreciation And Amortization	236.6K	228.5K	6.7M	7.1M

Interest Expense Depreciation And Amortization

Telix Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Good Will	Non Current Liabilities Total	Inventory	Other Current Assets	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock
Total Assets		0.98	0.79	0.96	0.78	0.97	0.87	-0.74	-0.78	0.93	0.82	0.96	0.97	0.82	0.95	0.73	0.85	0.86	0.88	0.94	0.98	0.87	0.91	0.95
Short Long Term Debt Total	0.98		0.73	0.99	0.62	1.0	0.91	-0.64	-0.88	0.98	0.72	0.94	0.99	0.72	0.99	0.79	0.93	0.9	0.89	0.99	0.95	0.79	0.87	0.99
Other Current Liab	0.79	0.73		0.76	0.67	0.73	0.68	-0.39	-0.46	0.78	0.44	0.91	0.82	0.44	0.74	0.22	0.52	0.7	0.74	0.71	0.67	0.98	0.97	0.63
Total Current Liabilities	0.96	0.99	0.76		0.56	1.0	0.92	-0.56	-0.89	0.99	0.65	0.95	0.99	0.65	1.0	0.75	0.94	0.92	0.9	1.0	0.92	0.8	0.88	0.98
Total Stockholder Equity	0.78	0.62	0.67	0.56		0.6	0.47	-0.82	-0.25	0.5	0.89	0.7	0.62	0.89	0.55	0.37	0.34	0.45	0.54	0.51	0.79	0.78	0.73	0.58
Property Plant And Equipment Net	0.97	1.0	0.73	1.0	0.6		0.92	-0.62	-0.89	0.98	0.7	0.94	0.99	0.7	1.0	0.79	0.94	0.91	0.9	0.99	0.94	0.79	0.86	0.99
Current Deferred Revenue	0.87	0.91	0.68	0.92	0.47	0.92		-0.64	-0.94	0.92	0.59	0.86	0.91	0.59	0.93	0.82	0.93	1.0	0.99	0.93	0.84	0.71	0.8	0.92
Net Debt	-0.74	-0.64	-0.39	-0.56	-0.82	-0.62	-0.64		0.5	-0.49	-0.95	-0.57	-0.58	-0.95	-0.57	-0.74	-0.54	-0.61	-0.68	-0.57	-0.82	-0.52	-0.53	-0.68
Retained Earnings	-0.78	-0.88	-0.46	-0.89	-0.25	-0.89	-0.94	0.5		-0.89	-0.49	-0.74	-0.85	-0.49	-0.9	-0.9	-0.99	-0.93	-0.88	-0.92	-0.77	-0.49	-0.62	-0.92
Accounts Payable	0.93	0.98	0.78	0.99	0.5	0.98	0.92	-0.49	-0.89		0.56	0.95	0.99	0.56	0.99	0.7	0.93	0.92	0.9	0.99	0.87	0.81	0.89	0.95
Cash	0.82	0.72	0.44	0.65	0.89	0.7	0.59	-0.95	-0.49	0.56		0.65	0.66	1.0	0.65	0.71	0.57	0.55	0.62	0.63	0.9	0.59	0.6	0.74
Non Current Assets Total	0.96	0.94	0.91	0.95	0.7	0.94	0.86	-0.57	-0.74	0.95	0.65		0.98	0.65	0.94	0.58	0.8	0.87	0.88	0.93	0.89	0.95	0.98	0.89
Non Currrent Assets Other	0.97	0.99	0.82	0.99	0.62	0.99	0.91	-0.58	-0.85	0.99	0.66	0.98		0.66	0.99	0.7	0.9	0.91	0.91	0.98	0.92	0.86	0.93	0.96
Cash And Short Term Investments	0.82	0.72	0.44	0.65	0.89	0.7	0.59	-0.95	-0.49	0.56	1.0	0.65	0.66		0.65	0.71	0.57	0.55	0.62	0.63	0.9	0.59	0.6	0.74
Net Receivables	0.95	0.99	0.74	1.0	0.55	1.0	0.93	-0.57	-0.9	0.99	0.65	0.94	0.99	0.65		0.77	0.95	0.92	0.9	1.0	0.92	0.79	0.87	0.98
Good Will	0.73	0.79	0.22	0.75	0.37	0.79	0.82	-0.74	-0.9	0.7	0.71	0.58	0.7	0.71	0.77		0.9	0.79	0.77	0.8	0.81	0.32	0.44	0.87
Non Current Liabilities Total	0.85	0.93	0.52	0.94	0.34	0.94	0.93	-0.54	-0.99	0.93	0.57	0.8	0.9	0.57	0.95	0.9		0.92	0.88	0.96	0.84	0.57	0.68	0.96
Inventory	0.86	0.9	0.7	0.92	0.45	0.91	1.0	-0.61	-0.93	0.92	0.55	0.87	0.91	0.55	0.92	0.79	0.92		0.99	0.93	0.82	0.72	0.81	0.9
Other Current Assets	0.88	0.89	0.74	0.9	0.54	0.9	0.99	-0.68	-0.88	0.9	0.62	0.88	0.91	0.62	0.9	0.77	0.88	0.99		0.91	0.84	0.76	0.84	0.89
Total Liab	0.94	0.99	0.71	1.0	0.51	0.99	0.93	-0.57	-0.92	0.99	0.63	0.93	0.98	0.63	1.0	0.8	0.96	0.93	0.91		0.91	0.75	0.84	0.98
Total Current Assets	0.98	0.95	0.67	0.92	0.79	0.94	0.84	-0.82	-0.77	0.87	0.9	0.89	0.92	0.9	0.92	0.81	0.84	0.82	0.84	0.91		0.77	0.82	0.95
Short Term Debt	0.87	0.79	0.98	0.8	0.78	0.79	0.71	-0.52	-0.49	0.81	0.59	0.95	0.86	0.59	0.79	0.32	0.57	0.72	0.76	0.75	0.77		0.99	0.71
Intangible Assets	0.91	0.87	0.97	0.88	0.73	0.86	0.8	-0.53	-0.62	0.89	0.6	0.98	0.93	0.6	0.87	0.44	0.68	0.81	0.84	0.84	0.82	0.99		0.79
Common Stock	0.95	0.99	0.63	0.98	0.58	0.99	0.92	-0.68	-0.92	0.95	0.74	0.89	0.96	0.74	0.98	0.87	0.96	0.9	0.89	0.98	0.95	0.71	0.79

Click cells to compare fundamentals

Telix Pharmaceuticals Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Telix Stock Analysis

When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Telix Free Cash Flow Yield vs Capex To Depreciation Analysis

Free Cash Flow Yield vs Capex To Depreciation

Free Cash Flow Yield vs Capex To Depreciation Correlation Analysis

Correlation Coefficient

Free Cash Flow Yield

Capex To Depreciation

Telix Pharmaceuticals fundamental ratios Correlations

Telix Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Telix Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Net	+ 1.0	Short Long Term Debt Total
Property Plant And Equipment Net	+ 1.0	Total Current Liabilities
Net Receivables	+ 1.0	Total Current Liabilities
Total Liab	+ 1.0	Total Current Liabilities
Net Receivables	+ 1.0	Property Plant And Equipment Net
Inventory	+ 1.0	Current Deferred Revenue

Non Current Liabilities Total	- 0.99	Retained Earnings
Cash And Short Term Investments	- 0.95	Net Debt
Cash	- 0.95	Net Debt
Retained Earnings	- 0.94	Current Deferred Revenue
Inventory	- 0.93	Retained Earnings
Common Stock	- 0.92	Retained Earnings